Sandoz launches TYRUKO® (natalizumab-sztn) in US, as first and only multiple sclerosis biosimilar

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules TYRUKO® approved for all indications of reference medicine Tysabri®* Proven to be clinically equivalent to reference product in terms of efficacy and safety Expected to be biosimilar growth driver for company

The release as fetched from its publisher. sandoz.com ↗